Randomized controlled trials included in analysis (n = 19)
| Study identifier . | Accrual start year . | n . | Treatment . |
|---|---|---|---|
| LNH-98.530-32 | 1998 | 399 | CHOP-21 vs R-CHOP-21 |
| ECOG 4494/CALGB 979333 | 1998 | 546; 342 | R1: CHOP-21 vs R-CHOP-21; R2: observation vs rituximab |
| LNH-98.334 | 1999 | 474; 269 | R1: ACE vs ACVBP*; R2: observation vs rituximab |
| RICOVER-6035 | 2000 | 1215 | 6 cycles CHOP-14 vs 8 cycles CHOP-14 vs 6 cycles R-CHOP-14 vs 8 cycles R-CHOP-14 |
| MInT36,37 | 2000 | 796 | CHOP-like vs R-CHOP-like |
| DSHNHL 2002-138 | 2003 | 261 | R-CHOEP-14 vs R-MegaCHOEP followed by ASCT |
| ANZINTER339 | 2003 | 224 | R-CHOP-21 vs R-miniCEOP |
| LNH03-1B40 | 2003 | 223 | ACVBP† vs R-ACVBP† |
| LNH03-2B41 | 2003 | 379 | R-CHOP-21 vs R-ACVBP† |
| LNH03-6B42 | 2003 | 600 | R-CHOP-14 vs R-CHOP-21 |
| NHL1343 | 2004 | 681 | Observation vs rituximab |
| PIX20344 | 2005 | 122 | R-CHOP-21 vs R-CPOP |
| R-CHOP-14 vs R-CHOP-2145 | 2005 | 1062 | R-CHOP-14 vs R-CHOP-21 |
| MAIN46 | 2007 | 748 | R-CHOP-14 or R-CHOP-21 vs RA-CHOP-14 or RA-CHOP-21 |
| PYRAMID7 | 2009 | 206 | R-CHOP-21 vs VR-CHOP |
| ECOG-ACRIN 141247 | 2013 | 280 | R-CHOP-21 vs R2CHOP |
| PHOENIX48 | 2013 | 844 | R-CHOP-21 vs R-CHOP + brutinib |
| ROBUST49 | 2015 | 570 | R-CHOP-21 vs R-CHOP + lenalidomide |
| POLARIX50 | 2017 | 875 | R-CHOP-21 vs R-CHP + polatuzumab vedotin |
| Study identifier . | Accrual start year . | n . | Treatment . |
|---|---|---|---|
| LNH-98.530-32 | 1998 | 399 | CHOP-21 vs R-CHOP-21 |
| ECOG 4494/CALGB 979333 | 1998 | 546; 342 | R1: CHOP-21 vs R-CHOP-21; R2: observation vs rituximab |
| LNH-98.334 | 1999 | 474; 269 | R1: ACE vs ACVBP*; R2: observation vs rituximab |
| RICOVER-6035 | 2000 | 1215 | 6 cycles CHOP-14 vs 8 cycles CHOP-14 vs 6 cycles R-CHOP-14 vs 8 cycles R-CHOP-14 |
| MInT36,37 | 2000 | 796 | CHOP-like vs R-CHOP-like |
| DSHNHL 2002-138 | 2003 | 261 | R-CHOEP-14 vs R-MegaCHOEP followed by ASCT |
| ANZINTER339 | 2003 | 224 | R-CHOP-21 vs R-miniCEOP |
| LNH03-1B40 | 2003 | 223 | ACVBP† vs R-ACVBP† |
| LNH03-2B41 | 2003 | 379 | R-CHOP-21 vs R-ACVBP† |
| LNH03-6B42 | 2003 | 600 | R-CHOP-14 vs R-CHOP-21 |
| NHL1343 | 2004 | 681 | Observation vs rituximab |
| PIX20344 | 2005 | 122 | R-CHOP-21 vs R-CPOP |
| R-CHOP-14 vs R-CHOP-2145 | 2005 | 1062 | R-CHOP-14 vs R-CHOP-21 |
| MAIN46 | 2007 | 748 | R-CHOP-14 or R-CHOP-21 vs RA-CHOP-14 or RA-CHOP-21 |
| PYRAMID7 | 2009 | 206 | R-CHOP-21 vs VR-CHOP |
| ECOG-ACRIN 141247 | 2013 | 280 | R-CHOP-21 vs R2CHOP |
| PHOENIX48 | 2013 | 844 | R-CHOP-21 vs R-CHOP + brutinib |
| ROBUST49 | 2015 | 570 | R-CHOP-21 vs R-CHOP + lenalidomide |
| POLARIX50 | 2017 | 875 | R-CHOP-21 vs R-CHP + polatuzumab vedotin |
ACE, doxorubicin, cyclophosphamide, and etoposide; ASCT, autologous stem cell transplantation; CHOP-21, cyclophosphamide, doxorubicin, vincristine, and prednisone given every 21 days; DSHNHL, Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome; ECOG-ACRIN, Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network; HDT, high-dose therapy; MInT, Mabthera International Trial; R1, first randomization; R2, second randomization; R2CHOP, R-CHOP plus lenalidomide; RA-CHOP, R-CHOP plus bevacizumab; R-ACVBP, ACVBP plus rituximab; R-CHOEP-14, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone given every 14 days; R-CHOP-21, rituximab + CHOP given every 21 days; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CPOP, rituximab, cyclophosphamide, pixantrone, vincristine, and prednisone; R-MegaCHOEP, R-CHOEP with dose-escalated cyclophosphamide, etoposide, and doxorubicin; R-miniCEOP, rituximab, cyclophosphamide, epirubicin, vinblastine, and prednisone; VR-CHOP, R-CHOP plus bortezomib.
ACVBP, doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone.
ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone.